BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla ...
SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
The ROR family of proteins includes ROR1 and ROR2 – receptor tyrosine kinases. ROR1 is especially interesting to pharmacologists as it has only been observed in cancerous and embryonic cells, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback